TruNormal Healthy Control CSF Biospecimens and Matched Products

... resulting in an annual loss of approximately $28 billion in the U.S. alone.¹ The common practice among numerous providers is categorizing their specimens as “normal” in the absence of diagnosed neurological pathologies.

This approach fails to adequately rule out the presence of subclinical or asymptomatic neurological diseases.

However, ignoring undetected pathologies injects bias into research, leading to:

Flawed validation of biomarkers
Unreliable predictive models
Misguided clinical trial design
Inaccurate pharmacodynamic analysis
Complication in drug efficacy assessment

...and, ultimately, to avoidable obstacles in the regulatory approval process.

FROM BENCH TO BREAKTHROUGH:

A Massive Repository of Truly Normal Samples at Your Fingertips

In light of these challenges, your choice of high-quality human biospecimens becomes essential in ensuring the success of your drug discovery and development efforts.

Unlike the typical “normal” biospecimens from many suppliers, our TruNormal® samples come exclusively from donors who are genuinely normal, ensuring that researchers are equipped with samples that are not just labeled normal but embody true physiological normalcy. These TruNormal® samples can be matched to our banked diseased material.

Figure 1: Matched samples. Our vast repository enables researchers around the globe to source samples from diseased donors corresponding to the samples from healthy TruNormal® controls.

Adding Clinical Depth to Your Data Analysis

Our samples include detailed clinical data like MMSE and MoCA scores, as well as biomarker levels, so that you can be sure our donors are genuinely normal. This enhances sample relevance and offers a focused approach to research, stratification of cognitive abilities, and insightful correlations charting the progression of neurologic conditions.

Each of our samples is paired with a comprehensive case report and includes a thorough medical history from A (such as ApoE genotype) to Z (like Zolpidem abuse).

Our donors, even healthy controls, undergo a variety of clinical tests.

You’ll get insights into the donor’s social background and education level, along with their alcohol and nicotine habits. We also include their current medications, their neuropsychiatric history, biomarkers, and repeat cognitive tests, including MMSE, MOCA, ADAS-COG, CDR, and IADL.²

REPEAT COGNITIVE TESTS

MMSE score progression over ten visits, in addition to our longitudinally collected biospecimens, allows for more accurate control of confounding variables and substantially expands the scope of investigational opportunities. In this figure, donors with Alzheimer’s Disease, Mild Cognitive Impairment, and TruNormal® controls are considered.

Each sample is collected in the United States through our network of thoroughly vetted IRB-approved clinical sites.

Fill out the form to help accelerate your research and unlock access to an unprecedented repository of human biological samples.

¹Freedman et al. (2015). The Economics of Reproducibility in Preclinical Research. PLOS Biology

^{2 Depending on the collection protocol and underlying neurologic condition.}

SUBCLINICAL DISEASES IN 'HEALTHY' SPECIMENS SKEW DRUG DISCOVERY EFFORTS

Over 50% of preclinical studies in life science research are irreproducible...

FROM BENCH TO BREAKTHROUGH:

DATA-RICH SAMPLES FROM A TO Z:

Request our Inventory

Unlock the Ordinary: Access the Essential Truly Normal Sample Repository for Your Research Needs

Recent Blogs

Subscribe